At Alexion, our mission is to transform the lives of people affected by rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. 

For over three decades, patients and their caregivers have been at the centre of everything we do. Everyday, we are inspired to think differently and follow the science in order to create better outcomes for them and their families. Our mission is driven by understanding who they are as unique individuals, not just their disease. 

In Switzerland, we work across various rare diseases and devastating conditions, including:

  • Paroxysmal Nocturnal Haemoglobinuria (PNH) – a rare, chronic, progressive and potentially life-threatening blood disorder. It is characterised by red blood cell destruction within blood vessels (also known as intravascular haemolysis) and white blood cell and platelet activation, which can result in thrombosis (blood clots).
  • Atypical Haemolytic Uraemic Syndrome (aHUS) – a rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots.
  • Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN) – a rare, progressive, genetic condition characterized by non-malignant (non-cancerous) tumors called plexiform neurofibromas (PN) that develop in the brain, and along the spinal cord and nerve.
  • Generalised Myasthenia Gravis (gMG) – a rare, autoimmune neuromuscular disease characterised by loss of muscle function and severe muscle weakness.
  • Neuromyelitis Optica Spectrum Disorder (NMOSD) – a rare autoimmune disease of the central nervous system, characterised by unpredictable relapses which can result in cumulative disability.
  • Hypophosphatasia (HPP) – a rare, genetic (inherited), metabolic disease characterized by impaired mineralization (“calcification”), the process that hardens and strengthens bones and teeth. This can lead to poor growth and development, weakness and deformity of bones and other skeletal abnormalities, and premature loss of teeth with the root intact.
  • Lysosomal Acid Lipase Deficiency (LAL-D) – a genetic, and progressive ultra-rare metabolic disease associated with multiorgan damage in infant, paediatric and adult patients, and premature death in infants.

Clinical Trials

Alexion works with clinicians and the wider healthcare community to undertake carefully planned clinical studies designed to help deliver a better tomorrow for people living with rare diseases and devastating conditions.

We lead the way in rare disease clinical trial innovation by tailoring core elements of the clinical trial process to meet the unique needs of the rare disease patients we aim to serve. Our close ties to the rare disease community and our patient-centric approach to clinical trials are the keys to our success. Conducting clinical research in rare diseases is complex and challenging, and the risk of failure is high. Yet Alexion continues to innovate and evolve into new areas where there is great unmet need and an opportunity to help people fully live their best lives.

Alexion’s clinical trials are listed on clinicaltrials.gov.


To find out more about career opportunities at Alexion in your country, please visit our Careers section and search for job opportunities by location.